Tritace 10

Leaflet accompanying the packaging: information for the user

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Tritace 10 (Cardace 10 mg), 10 mg, tablets

Ramipril
Tritace 10 and Cardace 10 mg are different trade names for the same medicine.

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Tritace 10 and what is it used for
• 2. Important information before taking Tritace 10
• 3. How to take Tritace 10
• 4. Possible side effects
• 5. How to store Tritace 10
• 6. Contents of the packaging and other information

1. What is Tritace 10 and what is it used for

Tritace 10 contains the active substance ramipril. It belongs to a group of medicines called ACE inhibitors (angiotensin-converting enzyme inhibitors).
Tritace 10 works by:

• reducing the production of substances in the body that increase blood pressure,
• reducing tension and dilating blood vessels,
• making it easier for the heart to pump blood throughout the body.

Tritace 10 can be used to:

• treat high blood pressure (hypertension),
• reduce the risk of heart attack or stroke,
• reduce the risk of or delay the progression of kidney problems (regardless of whether the patient has diabetes),
• treat heart failure, when the heart is not pumping enough blood to the rest of the body,
• treat heart failure after a heart attack.

2. Important information before taking Tritace 10

When not to take Tritace 10

• If the patient is allergic to ramipril, another ACE inhibitor, or any of the other ingredients of this medicine (listed in section 6). Symptoms of an allergic reaction may include: rash, difficulty swallowing or breathing, swelling of the lips, face, throat, or tongue.
• If the patient has ever had a severe allergic reaction called "angioedema". Symptoms include: itching, hives, red spots on the palms, soles, and throat, swelling of the throat and tongue, swelling around the eyes and lips, difficulty breathing and swallowing.
• If the patient is taking or has taken sacubitril in combination with valsartan, a medicine used to treat chronic (long-term) heart failure in adults.
• If the patient is undergoing dialysis or other blood filtration. Depending on the type of equipment used, Tritace 10 may not be a suitable medicine.
• If the patient has kidney problems related to reduced blood flow to the kidneys (renal artery stenosis).
• During the last 6 months of pregnancy (see below "Pregnancy and breastfeeding").
• If blood pressure is very low or unstable - the doctor will recommend frequent blood pressure checks.
• If the patient has diabetes or kidney problems and is being treated with a blood pressure-lowering medicine containing aliskiren.

If any of the above situations apply to the patient, they should not take Tritace 10. In case of doubts about taking this medicine, the patient should consult a doctor before starting to take Tritace 10.

Warnings and precautions

Before starting to take Tritace 10, the patient should discuss it with their doctor or pharmacist.

• If the patient has heart, liver, or kidney disease.
• If the patient has recently lost a significant amount of electrolytes or fluids (through vomiting, diarrhea, excessive sweating, a low-sodium diet, or long-term use of diuretics or dialysis).
• If the patient is to undergo desensitization treatment for bee or wasp stings (allergy shots).
• If the patient is to receive anaesthetics. They may be used during surgical or dental procedures. It may be necessary to stop taking Tritace 10 on the day before the procedure, in case of doubts, the patient should consult their doctor.
• If the patient has high levels of potassium in the blood (as shown by blood tests).
• If the patient is taking medicines or has conditions that may lower sodium levels in the blood. The doctor may recommend regular blood tests, especially to check sodium levels in the blood, particularly in elderly patients.
• If the patient is taking medicines that may increase the risk of angioedema (severe allergic reaction), such as mTOR inhibitors (e.g. temsirolimus, everolimus, sirolimus), wildagliptin, NEP inhibitors (e.g. racecadotril), or sacubitril in combination with valsartan (see section 2 "When not to take Tritace 10").
• If the patient has collagenosis, such as scleroderma or systemic lupus erythematosus.
• The patient should tell their doctor if they are pregnant, think they may be pregnant, or are planning to have a baby. It is not recommended to take Tritace 10 during the first 12 weeks of pregnancy, and it should not be taken from the 13th week of pregnancy, as it may harm the baby. If the patient becomes pregnant while taking Tritace 10, they should inform their doctor immediately. Before planned pregnancy, the treatment should be changed to a suitable alternative.
• If the patient is taking any of the following medicines used to treat high blood pressure:
• an angiotensin II receptor antagonist (AIIRA), also known as a sartan, e.g. valsartan, telmisartan, irbesartan, especially if the patient has kidney problems related to diabetes,
• aliskiren. The doctor may recommend regular monitoring of kidney function, blood pressure, and electrolyte levels (e.g. potassium) in the blood. See also section 2 "When not to take Tritace 10".

Children and adolescents

Tritace 10 should not be used in children and adolescents under 18 years of age, as the safety and efficacy of Tritace 10 have not been established.
If any of the above situations apply (or if there are any doubts), the patient should consult a doctor before starting to take Tritace 10.

Tritace 10 and other medicines

The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or might take. Tritace 10 may affect the way other medicines work, and other medicines may affect the way Tritace 10 works.
The patient should tell their doctor about the following medicines. They may reduce the effect of Tritace 10:

• Pain and anti-inflammatory medicines (e.g. non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or indomethacin and aspirin).
• Medicines used to treat low blood pressure, shock, heart failure, asthma, or allergies, such as ephedrine, noradrenaline, or adrenaline. The doctor will check the patient's blood pressure.

The patient should tell their doctor about the following medicines. They may increase the risk of side effects when taken with Tritace 10:

• sacubitril in combination with valsartan - used to treat chronic (long-term) heart failure in adults (see section 2 "When not to take Tritace 10"),
• pain and anti-inflammatory medicines (e.g. non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or indomethacin and aspirin),
• cancer medicines (chemotherapy),
• medicines used to prevent transplant rejection, such as cyclosporine,
• diuretics (water tablets), such as furosemide,
• medicines that increase potassium levels in the blood, such as spironolactone, triamterene, amiloride, potassium salts, trimethoprim (used alone or in combination with sulfamethoxazole for the treatment of bacterial infections) and heparin (a blood thinner),
• corticosteroids, such as prednisolone,
• allopurinol (used to reduce uric acid levels in the blood),
• procainamide (used to treat irregular heart rhythms),
• temsirolimus (used to treat cancer),
• sirolimus, everolimus (used to prevent transplant rejection),
• wildagliptin (used to treat type 2 diabetes),
• racecadotril (used to treat diarrhea),
• the doctor may recommend a change in dose and/or take other precautions if the patient is taking an angiotensin II receptor antagonist (AIIRA) or aliskiren (see also sections 2 "When not to take Tritace 10" and "Warnings and precautions"). The patient should tell their doctor about the following medicines. Their effect may be altered when taken with Tritace 10:
  • medicines used to treat diabetes, such as oral glucose-lowering medicines and insulin. Tritace 10 may lower blood glucose levels. During treatment with Tritace 10, the patient's blood glucose levels should be regularly checked;
  • lithium (used to treat mental illnesses). Tritace 10 may increase lithium levels in the blood. The doctor will monitor lithium levels in the blood.

  If any of the above situations apply to the patient (or if there are any doubts), they should consult a doctor before starting to take Tritace 10.

  Tritace 10 with food and drink

  • Drinking alcohol while taking Tritace 10 may cause dizziness and fainting. In case of doubts about the amount of alcohol allowed while taking Tritace 10, the patient should discuss it with their doctor regarding the potential interaction between blood pressure-lowering medicines and alcohol.
  • Tritace 10 can be taken with or without food.

  Pregnancy and breastfeeding

  Pregnancy
  If the patient is pregnant, breastfeeding, thinks they may be pregnant, or is planning to have a baby, they should consult a doctor before taking this medicine. Tritace 10 should not be taken during the first 12 weeks of pregnancy and should not be taken from the 13th week of pregnancy, as it may harm the baby. If the patient becomes pregnant while taking Tritace 10, they should inform their doctor immediately. Before planned pregnancy, the treatment should be changed to a suitable alternative.
  Breastfeeding
  The patient should not take Tritace 10 if they are breastfeeding.
  Before taking any medicine, the patient should consult a doctor or pharmacist.

  Driving and using machines

  While taking Tritace 10, the patient may experience dizziness. The risk of dizziness is higher at the start of treatment with Tritace 10 and after increasing the dose. If the patient experiences dizziness, they should not drive, use tools, or operate machinery.

  Tritace 10 contains sodium

  The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially "sodium-free".

  3. How to take Tritace 10

  This medicine should always be taken exactly as prescribed by the doctor. In case of doubts, the patient should consult a doctor or pharmacist.
  Tritace 2.5 (2.5 mg), Tritace 5 (5 mg), and Tritace 10 (10 mg) are available.

  Dosage

  Treatment of high blood pressure

  • The initial dose is usually 1.25 mg or 2.5 mg once a day.
  • The doctor may adjust the dose of Tritace 10 until blood pressure is controlled.
  • The maximum dose is 10 mg once a day.
  • If the patient is taking diuretics (water tablets), the doctor may stop or reduce the dose of the diuretic before starting treatment with Tritace 10. Prevention of heart attack or stroke
  • The initial dose is usually 2.5 mg once a day.
  • The doctor may decide to increase the dose.
  • The usual dose is 10 mg once a day. Reducing or delaying the progression of kidney problems
  • The initial dose is usually 1.25 mg or 2.5 mg once a day.
  • The doctor may adjust the dose of Tritace 10.
  • The usual dose is 5 mg or 10 mg once a day. Treatment of heart failure
  • The initial dose is usually 1.25 mg once a day.
  • The doctor may adjust the dose of Tritace 10.
  • The maximum dose is 10 mg per day. It is recommended to take the medicine in two divided doses. Treatment after a heart attack
  • The initial dose is usually 1.25 mg to 2.5 mg once a day.
  • The doctor may adjust the dose of Tritace 10.
  • The usual dose is 10 mg per day. It is recommended to take the medicine in two divided doses.

  Elderly patients
  The doctor will recommend a lower-than-usual initial dose, which will then be gradually increased.

  Taking the medicine

  • The medicine should be taken orally, once a day, at the same time.
  • The patient should swallow the tablets with a drink.
  • The tablets should not be crushed or chewed.

  Overdose of Tritace 10

  The patient should contact a doctor or go to the nearest hospital emergency department.
  The patient should not drive themselves, but should ask someone to drive them to the hospital or call an ambulance. The patient should take the packaging of the medicine with them, so that the doctor knows what medicine has been taken.

  Missing a dose of Tritace 10

  • If a dose is missed, the patient should take the next planned dose at the usual time.
  • The patient should not take a double dose to make up for a missed dose.

  In case of further doubts about taking this medicine, the patient should consult a doctor or pharmacist.

  4. Possible side effects

  Like all medicines, Tritace 10 can cause side effects, although not everybody gets them.

  If the patient notices any of the following serious side effects, they should stop taking Tritace 10 and contact their doctor immediately – urgent medical attention may be required:

  • Swelling of the face, lips, or throat, making it difficult to swallow or breathe, as well as itching and rash. These may be symptoms of a severe allergic reaction to Tritace 10.
  • Severe skin reactions, including rash, ulcers in the mouth, worsening of existing skin conditions, redness, blisters, or peeling of the skin (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or erythema multiforme).

  If the patient experiences any of the following, they should tell their doctor promptly:

  • Rapid heartbeat, irregular heartbeat, chest pain, feeling of pressure in the chest, or worsening of existing heart conditions, including heart attack or stroke.
  • Shortness of breath or cough. These may indicate lung problems.
  • Easy bruising, prolonged bleeding, or any signs of bleeding (e.g. bleeding from the gums), purpura, or frequent infections, sore throat, and fever, fatigue, weakness, dizziness, or pale skin. These may indicate blood or bone marrow disorders.
  • Severe abdominal pain, which may radiate to the back. This may be a symptom of pancreatitis.
  • Fever, chills, weakness, loss of appetite, abdominal pain, nausea, or vomiting, yellowing of the skin or whites of the eyes (jaundice). These may be symptoms of liver problems, such as inflammation or liver damage.

  Other side effects

  The patient should tell their doctor if any of the following symptoms get worse or persist for more than a few days.
  Common(may affect up to 1 in 10 people)

  • Headache or feeling tired,
  • Dizziness; the risk is higher at the start of treatment with Tritace 10 and after increasing the dose,
  • Fainting, low blood pressure, especially when changing from a lying to a sitting or standing position,
  • Dry, persistent cough, sinusitis, or bronchitis, shortness of breath,
  • Abdominal or intestinal pain, diarrhea, indigestion, nausea, or vomiting,
  • Rash with or without raised patches,
  • Chest pain,
  • Muscle cramps or pain,
  • High levels of potassium in the blood, as shown by laboratory tests.

  Uncommon(may affect up to 1 in 100 people)

  • Balance disorders (dizziness),
  • Itching of the skin and sensory disturbances, such as numbness, tingling, prickling, burning, or crawling sensation on the skin (paresthesia),
  • Loss of or altered sense of taste,
  • Sleep disturbances,
  • Depression, anxiety, nervousness, or restlessness,
  • Nasal congestion, difficulty breathing, or worsening of asthma,
  • Intestinal angioedema, characterized by abdominal pain, vomiting, and diarrhea,
  • Heartburn, constipation, or dry mouth,
  • Increased urination during the day,
  • Excessive sweating,
  • Loss of or decreased appetite (anorexia),
  • Fast or irregular heartbeat,
  • Swelling of the hands and feet; may be a sign of water retention,
  • Sudden flushing of the face,
  • Blurred vision,
  • Joint pain,
  • Fever,
  • Impotence, decreased libido in men and women,
  • Increased levels of certain white blood cells (eosinophilia) in laboratory tests,
  • Abnormal laboratory test results indicating changes in the liver, pancreas, or kidneys.

  Rare(may affect up to 1 in 1,000 people)

  • Feeling of uncertainty, confusion, or disorientation,
  • Red, swollen tongue,
  • Excessive peeling of the skin, itchy papular rash,
  • Nail disorders (e.g. loosening or separation of the nail from the nail bed),
  • Rash or bruising of the skin,
  • Spots on the skin and cold extremities,
  • Redness, itching, swelling, and tearing of the eyes,
  • Hearing or ringing in the ears,
  • Weakness,
  • Decreased levels of red blood cells, white blood cells, or platelets, or hemoglobin levels in laboratory tests.

  Very rare(may affect up to 1 in 10,000 people)

  • Sensitivity to sunlight.

  Other reported side effects:

  If any of the following symptoms get worse or persist for more than a few days, the patient should tell their doctor.

  • Difficulty concentrating,
  • Swelling of the lips,
  • Low levels of blood cells, as shown by laboratory tests,
  • Low levels of sodium in the blood, as shown by laboratory tests,
  • Dark urine (concentrated urine), nausea, or vomiting, muscle cramps, confusion, and seizures, which may be due to abnormal antidiuretic hormone (ADH) secretion. If the patient experiences any of these symptoms, they should immediately consult their doctor,
  • Changes in finger color upon cooling and feeling of tingling or pain upon warming (Raynaud's phenomenon),
  • Breast enlargement in men,
  • Slowed or impaired reactions,
  • Burning sensation,
  • Disturbances of smell,
  • Hair loss.

  Reporting side effects

  If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
  By reporting side effects, more information can be gathered on the safety of this medicine.

  5. How to store Tritace 10

  The medicine should be stored out of sight and reach of children.
  The medicine should not be taken after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
  There are no special storage precautions.
  Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

  6. Contents of the packaging and other information

  What Tritace 10 contains

  The active substance is ramipril.
  Each tablet contains 10 mg of ramipril.
  The other ingredients are hypromellose, maize starch, microcrystalline cellulose, sodium stearyl fumarate.

  What Tritace 10 looks like and contents of the pack

  The tablets are white or almost white, oblong, scored, 7 x 4.5 mm in size, with "HMO/HMO" engraved on one side. The tablet can be divided into equal doses.
  Tritace 10 tablets are packaged in PVC/Aluminium blisters containing 28 tablets.
  For more detailed information, the patient should consult the marketing authorization holder or parallel importer.

  Marketing authorization holder in Lithuania, country of export:

  sanofi-aventis groupe
  54, rue La Boétie
  75008 Paris
  France

  Manufacturer:

  Sanofi S.r.l.
  Strada Statale 17, Km 22, 67019 Scoppito (L’Aquila), Italy
  Delpharm Dijon
  6, boulevard de l’Europe, 21800 Quetigny, France
  S.C. ZENTIVA S.A.
  B-dul Theodor Pallady nr. 50, Sector 3, Bucharest, 032266, Romania
  Sanofi Aventis Deutschland GmbH
  Industriepark Hoechst Bruningstrasse 50
  D-65926 Frankfurt am Main, Germany

  Parallel importer:

  InPharm Sp. z o.o.
  ul. Strumykowa 28/11
  03-138 Warsaw

  Repackaged by:

  InPharm Sp. z o.o. Services sp. k.
  ul. Chełmżyńska 249
  04-458 Warsaw
  Lithuanian marketing authorization number, country of export: LT/1/97/1617/005
  Parallel import authorization number:49/21
  Date of leaflet approval: 24.08.2022
  [Information about the trademark]